Influence of long-term volume therapy with hydroxyethyl starch on leukocytes in patients with acute stroke

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 6, 2003, Pages 402-406

  Woessner, Ralph ^a   Grauer, Markus T ^a   Dieterich, Hans Jürgen ^b   Treib, Wolfgang ^c   Stoll, Martin ^a   Treib, Johannes ^a  

^a Westpfalz Klinikum GmbH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Dental Practice   (Germany)

Author keywords

CAS 9005 27 0; Hydroxyethyl starch, acute stroke, effect on leukocytes, effect on fibronectin

Indexed keywords

FIBRONECTIN; HEMOGLOBIN; HETASTARCH; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BRAIN PERFUSION; CLINICAL ARTICLE; DRUG MECHANISM; HEMODILUTION; HEMOSTASIS; HUMAN; IMMUNITY; LEUKOCYTE; MALE; NEUTROPHIL; PHAGOCYTOSIS; PLASMA VISCOSITY; RETICULOENDOTHELIAL SYSTEM; STROKE; THROMBOCYTE VOLUME;

EID: 0038772410     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297127     Document Type: Article

References (32)

1. Yoshida, M., Yamashita, T., Matsuo, J. et al., Enzymic degradation of hydroxyethyl starch. Part I. Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch. Stärke 25, 373 (1973)
2. Yoshida, M., Kishikawa, T., A study of hydroxyethyl starch. Part II. Degradation - sites of hydroxyethyl starch by pig pankreas alpha-amylase. Starch/Stärke 36, 167 (1984)
3. Yoshida, M., Minami, Y., Kishikawa, T., A study of hydroxyethyl starch. Part III. Comparison of metabolic fates between 2-0-hydroxyethyl starch and 6-0-hydroxyethyl starch in rabbits. Starch/Stärke 36, 209 (1984)
4. Treib, J., Haass, A., Pindur, G. et al., HES 200/0,5 is not HES 200/0,5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb. Haemost. 74, 1452 (1995)
5. Haass, A., Treib, J., Stoll, M., Hemorheological parameters of hydroxyethylstarch 200/0,62 as a basis for hemodilution. Clin. Hemorheol. 12 (Suppl. 1), 17 (1992)
6. Haass, A., Stoll, M., Treib, J., Hemodilution in cerebral circulatory disturbances: Indications, implementation, additional drug treatment and alternatives; in J. Koscielny, H. Kiesewetter, F. Jung et al. (eds,), Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macroand microcirculation, pp. 53-114, Springer, Berlin-Heidelberg etc. (1992)
7. Treib, J., Haass, A., Pindur, G. et al., All medium starches are not the same. Influence of degree of substitution of hydroxyethyl starch on plasma volume, hemorheologic conditions, and coagulation. Transfusion 36, 450 (1996)
8. Treib, J., Haass, A., Pindur, G. et al., Highly substituted hydroxyethyl starch (HES 200/0.62) leads to a type I von Willebrand syndrome after repeated administration. Haemostasis 26, 210 (1996)
9. Treib, J., Haass, A., Pindur, G., Review article: Coagulation disorders caused by hydroxyethyl starch. Thromb. Haemost. 78, 974 (1997)
10. Trumble, E. R., Muizelaar, J. P., Myseros, J. S. et al., Coagulopathy with the use of hetastarch in the treatment of vasospasm. J. Neurosurg. 82, 44 (1995)
11. Treib, J., Haass, A., Hydroxyethyl starch. J. Neurosurg. 86, 574 (1997)
12. Treib, J., Haass, A., Pindur, G. et al., Influence of low molecular weight hydroxyethyl starch on hemostasis and hemorheology. Haemostasis 26, 258 (1996)
13. Treib, J., Haass, A., Pindur, G. et al., Influence on intravascular molecular weight of hydroxyethyl starch on platelets during a long-term hemodilution. Eur. J. Hematol. 56, 168 (1996)
14. Thompson, C. B., Eaton, K. A., Princiotta, S. M. et al., Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br. J. Haematol. 50, 509 (1982)
15. Treib, J., Haass, A., Pindur, G. et al., Decrease of fibronectin following repeated infusion of highly substituted hydroxyethyl starch. Infusionsther. Transfusionsmed. 23, 71 (1996)
16. Förster, H., Wicarkzyk, C., Dudziak, R., Bestimmung der Plasmaelimination von Hydroxyäthylstärke und von Dextran mittels verbesserter analytischer Methodik. Infusionstherapie 2, 88 (1981)
17. Eigner, W. D., Hydroxyethylstärke, Molmassenbestimmung von Hydroxyethylstärke in Elektrolytlösung nach Temperaturbelastung. Krankenhauspharmazie 9, 20 (1988)
18. Kiesewetter, H,. Waldhausen, P., Schimetta, W. et al., Possible side effects of a HAES infusion and their treatment; in J. Koscielny, H. Kiesewetter, F. Jung et al. (eds.), Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macro- and microcirculation, pp. 165-170, Springer, Berlin-Heidelberg et al. (1992)
19. Thompson, W. L., Fukushima,T., Rutherford, R. B. et al., Intravasale Persistenz, Gewebsspeicherung und Ausscheidung von Hydroxyäthylstärke (HÄS). Infusionstherapie 6, 151 (1979)
20. Szepfalusi, Z., Parth, E., Jurecka, W. et al., Human monocytes and keratinocytes in culture ingest hydroxyethylstarch. Arch. Dermatol. Res. 285, 144 (1993)
21. Doran, J. E., A critical assessment of fibronectin's opsonic role for bacteria and microaggregates. Vox Sang. 45, 337 (1983)
22. Mork, T., Hancock, R. E. W., Mechanisms of nonopsonic phagocytosis of pseudomonas aeroginosa. Infect. Immun. 61, 3287 (1993)
23. Xie, D. L., Meyers, R., Homandberg, G. A., Release of elastase from monocytes adherent to fibronectin-gelatin surface. Blood 81, 186 (1993)
24. Ratliff, T. L., McCarthy, R., Telle, W. B. et al., Purification of a mycobacterial adhesis to fibronectin. Infect. Immun. 61, 1889 (1993)
25. Khosropour, R., Graninger, W., Lackner, F., Der Einfluß von Hämodilution mit Plasmaproteinlösung und Hydroxyäthylstärke auf das Plasmafibronektin. Anästh. Intensivther. Notfallmed. 19, 175 (1984)
26. Brodin, B., Hesselvik, F., von Schenk, H., Decrease of plasma fibronectin concentration following infusion of a gelatin-based plasma substitute in man. Scand J. clin. Lab. Invest. 44, 529 (1984)
27. Lackner, F., Graninger, W., Khosropour, R., Senkt Gelatine als Blutersatzmittel selektiv das Plasmafibronectin ? Anaesthesist 34, 470 (1985)
28. Lenz, G., Hempel, V., Junger, H. et al., Auswirkungen von Hydroxyäthylstärke, Oxypolygelatine und Humanalbumin auf die Phagozytosefunktion des Retikuloendothelialen Systems (RES) gesunder Probanden. Anaesthesist 35, 423 (1986)
29. Shatney, C. H., Chaudry, I. H., Hydroxyethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis. Circ. Shock 13, 21 (1984)
30. Schildt, B., Bouveng, R., Sollenberg, M., Plasma substitute induced impairment of the reticuloendothelial system function. Acta Chir. Scand. 141, 7 (1975)
31. Lukowsky, A., Mielke, F., Zur Rolle von Fibronectin bei der unspezifischen Abwehr aus immunologischer Sicht. Z. Gesamte Inn. Med. 41, 437 (1986)
32. Yang, K. D., Augustine, N. H., Shaio, M.-F. et al., Effects of fibronectin on actin organization and respiratory burst activity in neutrophils, monocytes, and macrophages. J. Cell. Physiol. 158, 347 (1994)